2022 Society of Urologic Cancer Annual Meeting recap - SUO/YUO research highlight

"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.

“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD

The median DOR among the 15 patients in the study was 24.4 months (range, 10.1 to 30.7 months).

The phase 3 CAPTAIN trial was launched following the pivotal TACT trial, which showed that TULSA provided durable disease control with low toxicity at 3 years’ follow-up in men with localized prostate cancer.

"Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.

“So I think what we can take away from this study is that just because your patient [has a higher BMI], doesn't mean that they're a poor candidate for a partial nephrectomy,” said Lachlan Shiver.